中国临床药理学杂志2016，Vol.32Issue(13)：1240-1243,4.DOI:10.13699/j.cnki.1001-6821.2016.13.026
舒尼替尼在治疗肾癌的不良反应及其单核苷酸多态性与血药浓度的相关性研究现状
Research progress of the relationship between adverse reaction, single nucleotide polymorphism and plasma concentration in renal carcinoma patients treated with sunitinib
张媛媛 1毕国放 1刘泽源 1曲恒燕1
作者信息
- 1. 军事医学科学院 附属医院 临床药理室，北京 100071
- 折叠
摘要
Abstract
There are definite effects of sunitinib molecular target therapy on renal carcinoma , but not all the patients diagnosed with renal carcino-ma could benefit from it.Single nucleotide polymorphism ( SNP ) could be related to point mutations of patients who couldn ’ t bear the toxicity that induced by sunitinib.Besides, the sunitinib induced toxicity could be influenced by the exposure of sunitinib in patient plasma .Therefore the aim of this article was to conduct a systematic review to the relation-ship among adverse reaction , SNPs and plasma concentration in renal carcinoma patients treated with sunitinib .关键词
肾癌/舒尼替尼/单核苷酸多态性/不良反应/血药浓度Key words
renal carcinoma/sunitinib/single nucleotide polymor-phism/adverse reaction/plasma concentration分类
医药卫生引用本文复制引用
张媛媛,毕国放,刘泽源,曲恒燕..舒尼替尼在治疗肾癌的不良反应及其单核苷酸多态性与血药浓度的相关性研究现状[J].中国临床药理学杂志,2016,32(13):1240-1243,4.
